Alzheimer's disease (AD) is a neurodegenerative disease associated with the loss of nerve cells in the brain. The disease is affected by multifactorial pathways and leads to changes in related biomolecular levels as AD progresses. Therefore, AD should be diagnosed with combined detection of several lesions to improve accuracy. Amyloid beta 1–40, 1–42 and τ (tau) protein are milestones in AD pathology and can be used as main screening and diagnostic target markers. Here, we suggest a highly selective biosensor for detection of AD core biomarkers on one platform through distinct localized surface plasmon resonance (LSPR) depending on gold nanoparticles shapes, called a shape-code biosensor. This plasmonic sensor consists of only gold nanoparticles and antibody, but does not need additory methods for precise separation from multifarious samples and identification of markers. Under physiological condition, we determined a detection limit of 34.9 fM for amyloid beta (Aβ) 1–40, 26 fM for Aβ 1–42 and 23.6 fM for τ protein corresponding to the ~ 1, ~ 2.23 and ~ 3.12 nm of Rayleigh scattering peak shift on shape-code plasmon system for each biomarker in mimicked blood. This is the first highly sensitive shape-code biosensor to detect AD biomarkers which can be used to diagnose AD easily in the future.
Bibliographical noteFunding Information:
This study was supported by the National Research Foundation of Korea (NRF) grants (Grant No. NRF-2016R1A2A1A05005465/2010-0027955 ) and grants ( 2014M1A8A1049278 ) from the Korea CCS R&D Center (Korea CCS 2020 Project) grant funded by the Korea government ( Ministry of Science and ICT ) in 2017. Appendix A
© 2017 Elsevier B.V.
- Alzheimer's disease (AD)
- Gold nanoparticles (AuNPs)
- Localized surface plasmon resonance (LSPR)
- Multiplex detection
- Plasmonic biosensors
ASJC Scopus subject areas
- Biomedical Engineering